Titre:
  • p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Auteur:Di Leo, Angelo; Tanner, M; Desmedt, Christine; Paesmans, Marianne; Cardoso, Fatima; Durbecq, Virginie; Chan, S; Perren, Thimothy J.; Aapro, Matti; Sotiriou, Christos; Piccart-Gebhart, Martine; Larsimont, Denis; Isola, Jorma; TAX 303 translational study team,
Informations sur la publication:Annals of oncology, 18, 6, page (997-1003)
Statut de publication:Publié, 2007-06
Sujet CREF:Sciences bio-médicales et agricoles
Cancérologie
Médecine pathologie humaine
Mots-clés:Cytotoxics
Molecular markers
Topoisomerase II alpha
MeSH keywords:Antineoplastic Agents -- therapeutic use
Breast Neoplasms -- drug therapy
Breast Neoplasms -- genetics
Breast Neoplasms -- pathology
Chromatography, High Pressure Liquid
DNA Primers
DNA, Neoplasm -- genetics
DNA, Neoplasm -- isolation & purification
Doxorubicin -- therapeutic use
Genes, p53
Mutation
Predictive Value of Tests
Probability
Protein Biosynthesis
Taxoids -- therapeutic use
Note générale:Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdm075
info:pii/mdm075
info:scp/34447314153
info:pmid/17369602